SG10201408164XA - Compositions and methods related to mrna translational enhancer elements - Google Patents

Compositions and methods related to mrna translational enhancer elements

Info

Publication number
SG10201408164XA
SG10201408164XA SG10201408164XA SG10201408164XA SG10201408164XA SG 10201408164X A SG10201408164X A SG 10201408164XA SG 10201408164X A SG10201408164X A SG 10201408164XA SG 10201408164X A SG10201408164X A SG 10201408164XA SG 10201408164X A SG10201408164X A SG 10201408164XA
Authority
SG
Singapore
Prior art keywords
translational enhancer
compositions
enhancer elements
methods related
mrna
Prior art date
Application number
SG10201408164XA
Inventor
Vincent P Mauro
Gerald M Edelman
Wei Zhou
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG10201408164XA publication Critical patent/SG10201408164XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSITIONS AND METHODS RELATED TO MRNA TRANSLATIONAL ENHANCER ELEMENTS Abstract 5 Provided are mRNA translationa! enhancer elements (TEEs), e.g., SEQ ID NOs: 1- 35. Also provided are translational enhancer polynucleotides that comprise one or more of the specific TEEs exemplified herein or their variants, homologs or functional derivatives. Further provided are expression vectors comprising such TEEs or translational enhancer 10 polynucleotides, as well as host cells and expression systems that harbor such vectors. Fig. 1 35
SG10201408164XA 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements SG10201408164XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US744007P 2007-12-11 2007-12-11

Publications (1)

Publication Number Publication Date
SG10201408164XA true SG10201408164XA (en) 2015-01-29

Family

ID=40386467

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201408162PA SG10201408162PA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG2013017025A SG188866A1 (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG10201408164XA SG10201408164XA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG10201408165WA SG10201408165WA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201408162PA SG10201408162PA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG2013017025A SG188866A1 (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201408165WA SG10201408165WA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements

Country Status (8)

Country Link
US (2) US8785611B2 (en)
EP (5) EP2527439B1 (en)
JP (3) JP5474816B2 (en)
CN (2) CN101939428B (en)
AU (1) AU2008335723C1 (en)
CA (2) CA2904904A1 (en)
SG (4) SG10201408162PA (en)
WO (1) WO2009075886A1 (en)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130230884A1 (en) * 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3590949B1 (en) 2010-10-01 2022-05-18 ModernaTX, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (en) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
JP2015513912A (en) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PT2922554T (en) 2012-11-26 2022-06-28 Modernatx Inc Terminally modified rna
US20140200261A1 (en) 2013-01-17 2014-07-17 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105849269B (en) 2013-11-12 2020-07-17 Vrije布鲁塞尔大学 RNA transcription vector and use thereof
EP4159741A1 (en) 2014-07-16 2023-04-05 ModernaTX, Inc. Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3461904A1 (en) 2014-11-10 2019-04-03 ModernaTX, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
SI3350333T1 (en) 2015-09-17 2022-04-29 ModernaTX,Inc. Polynucleotides containing a stabilizing tail region
ES2969082T3 (en) 2015-09-17 2024-05-16 Modernatx Inc Compounds and compositions for intracellular administration of therapeutic agents
ES2810701T5 (en) 2015-10-05 2024-07-11 Modernatx Inc Procedures for the therapeutic administration of messenger ribonucleic acid drugs
EP3362461B1 (en) 2015-10-16 2022-03-16 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
JP2018530587A (en) 2015-10-16 2018-10-18 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． mRNA cap analogs and methods of mRNA capping
HUE057877T2 (en) 2015-12-22 2022-06-28 Modernatx Inc Compounds and compositions for intracellular delivery of agents
EP4039699A1 (en) 2015-12-23 2022-08-10 ModernaTX, Inc. Methods of using ox40 ligand encoding polynucleotides
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US20190167811A1 (en) 2016-04-13 2019-06-06 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
CA3024625A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
CA3024507A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
ES2973443T3 (en) 2016-05-18 2024-06-20 Modernatx Inc Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
CA3024917A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Combinations of mrnas encoding immune modulating polypeptides and uses thereof
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
AU2017266948B2 (en) 2016-05-18 2024-07-04 Fundacion Para La Investigacion Medica Aplicada Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
CN109195621A (en) 2016-05-18 2019-01-11 莫得纳特斯公司 The polynucleotides and application thereof of encoding Interleukin 12 (IL12)
MA45052A (en) 2016-05-18 2019-03-27 Modernatx Inc POLYNUCLEOTIDES CODING FOR JAGGED1 FOR THE TREATMENT OF ALAGILLUS SYNDROME
JP2019525901A (en) 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Stabilized preparation of lipid nanoparticles
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
JP7332478B2 (en) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド Lipid nanoparticle formulation
AU2018234692B2 (en) 2017-03-15 2022-06-02 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
ES2952779T3 (en) 2017-05-18 2023-11-06 Modernatx Inc Modified messenger RNA comprising functional RNA elements
EP3638678A1 (en) 2017-06-14 2020-04-22 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Methods of preparing modified rna
MX2020002348A (en) 2017-08-31 2020-10-08 Modernatx Inc Methods of making lipid nanoparticles.
MA54676A (en) 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
US20210163928A1 (en) 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
JP7410135B2 (en) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
JP2022519557A (en) 2019-01-31 2022-03-24 モデルナティエックス インコーポレイテッド Method for preparing lipid nanoparticles
CA3128488A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Vortex mixers and associated methods, systems, and apparatuses thereof
EP3986480A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Messenger rna comprising functional rna elements and uses thereof
WO2020263883A1 (en) 2019-06-24 2020-12-30 Modernatx, Inc. Endonuclease-resistant messenger rna and uses thereof
CA3168902A1 (en) 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
CA3170150A1 (en) 2020-02-07 2021-08-12 Modernatx, Inc. Sars-cov-2 mrna domain vaccines
TW202204622A (en) 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 Nucleic acid vaccines for coronavirus
EP4077272B1 (en) 2020-04-09 2024-09-18 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticle composition
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
CN114206463B (en) 2020-06-30 2024-06-11 苏州艾博生物科技有限公司 Lipid compounds and lipid nanoparticle compositions
CN116710079A (en) 2020-07-24 2023-09-05 斯特兰德生物科技公司 Lipid nanoparticles comprising modified nucleotides
US20230053437A1 (en) 2020-08-20 2023-02-23 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
EP4217371A1 (en) 2020-09-25 2023-08-02 ModernaTX, Inc. Multi-proline-substituted coronavirus spike protein vaccines
US20240166707A1 (en) 2021-01-08 2024-05-23 Strand Therapeutics Inc. Expression constructs and uses thereof
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116615472A (en) 2021-01-14 2023-08-18 苏州艾博生物科技有限公司 Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2022155530A1 (en) 2021-01-15 2022-07-21 Modernatx, Inc. Variant strain-based coronavirus vaccines
AU2022208057A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
AU2022237382A1 (en) 2021-03-15 2023-09-28 Modernatx, Inc. Therapeutic use of sars-cov-2 mrna domain vaccines
EP4314332A2 (en) 2021-04-01 2024-02-07 ModernaTX, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
EP4322993A1 (en) 2021-04-13 2024-02-21 ModernaTX, Inc. Respiratory virus combination vaccines
EP4322994A1 (en) 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
CA3211623A1 (en) 2021-05-24 2022-12-01 Bo YING Lipid compounds and lipid nanoparticle compositions
US20240218353A1 (en) 2021-06-17 2024-07-04 Modernatx, Inc. Alternative rna purification strategies
WO2023018923A1 (en) 2021-08-13 2023-02-16 Modernatx, Inc. Multicolumn chromatography mrna purification
CA3234127A1 (en) 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
AR127312A1 (en) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
CN116064598B (en) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 Nucleic acid vaccine for coronavirus
WO2023069498A1 (en) 2021-10-22 2023-04-27 Senda Biosciences, Inc. Mrna vaccine composition
WO2023076658A1 (en) 2021-11-01 2023-05-04 Modernatx, Inc. Mass spectrometry of mrna
EP4426855A1 (en) 2021-11-05 2024-09-11 ModernaTX, Inc. Methods of purifying dna for gene synthesis
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
WO2023096858A1 (en) 2021-11-23 2023-06-01 Senda Biosciences, Inc. A bacteria-derived lipid composition and use thereof
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
CA3241492A1 (en) 2021-12-23 2023-06-29 Suzhou Abogen Biosciences Co., Ltd. Lipid compound and lipid nanoparticle composition
WO2023132885A1 (en) 2022-01-04 2023-07-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023137149A1 (en) 2022-01-14 2023-07-20 Modernatx, Inc. In vitro transcription dna purification and recycling
WO2023150256A1 (en) 2022-02-03 2023-08-10 Modernatx, Inc. Continuous precipitation for mrna purification
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
WO2023201296A1 (en) 2022-04-15 2023-10-19 Modernatx, Inc. Ribosomal engagement potency assay
AU2023262576A1 (en) 2022-04-26 2024-10-10 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2024010993A1 (en) 2022-07-06 2024-01-11 Modernatx, Inc. Primer design for cell-free dna production
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
TW202424187A (en) 2022-10-27 2024-06-16 美商輝瑞大藥廠 Rna molecules
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024097874A1 (en) 2022-11-03 2024-05-10 Modernatx, Inc. Chemical stability of mrna
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024151811A1 (en) 2023-01-11 2024-07-18 Modernatx, Inc. Personalized cancer vaccines
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof
WO2024163465A1 (en) 2023-01-30 2024-08-08 Modernatx, Inc. Epstein-barr virus mrna vaccines
WO2024191860A2 (en) 2023-03-10 2024-09-19 Modernatx, Inc. Nucleic acid influenza vaccines and respiratory virus combination vaccines
WO2024192277A2 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024206835A1 (en) 2023-03-30 2024-10-03 Modernatx, Inc. Circular mrna and production thereof
WO2024215721A1 (en) 2023-04-10 2024-10-17 Modernatx, Inc. Lyme disease vaccines
WO2024216162A1 (en) 2023-04-12 2024-10-17 Strand Therapeutics Inc. Synthetic circuits and uses thereof
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US6116184A (en) 1996-05-21 2000-09-12 Symetrix Corporation Method and apparatus for misted liquid source deposition of thin film with reduced mist particle size
WO1998037189A1 (en) * 1997-02-25 1998-08-27 Qbi Enterprises Ltd. Ires sequences with high translational efficiency and expression vectors containing the sequence
EP1030925A1 (en) * 1997-11-12 2000-08-30 Brigham & Women's Hospital, Inc. The translation enhancer element of the human amyloid precursor protein gene
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
EP1147188B1 (en) 1999-01-26 2007-05-16 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Internal ribosome entry site (ires), vector containing same and the uses thereof
WO2001055371A1 (en) * 2000-01-28 2001-08-02 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
AU2001250858A1 (en) * 2000-03-17 2001-10-03 Gene Logic, Inc. Methods of preparing amplified nucleic acid molecules
EP2329846B1 (en) 2000-09-08 2014-11-12 University Of Maryland, Baltimore Genetically engineered co-expression DNA vaccines, construction methods and uses thereof
JP5225087B2 (en) * 2005-08-24 2013-07-03 ザ スクリプス リサーチ インスティチュート Translation enhancer element-dependent vector system

Also Published As

Publication number Publication date
JP2011505831A (en) 2011-03-03
CA2708766A1 (en) 2009-06-18
CA2708766C (en) 2016-02-02
JP5474816B2 (en) 2014-04-16
CN101939428A (en) 2011-01-05
EP2527439B1 (en) 2014-03-26
SG10201408165WA (en) 2015-01-29
EP2584038B1 (en) 2014-06-25
EP2231859A1 (en) 2010-09-29
JP2014113163A (en) 2014-06-26
SG188866A1 (en) 2013-04-30
CN101939428B (en) 2014-05-07
US20130177581A1 (en) 2013-07-11
JP5873511B2 (en) 2016-03-01
EP2610340B1 (en) 2014-10-01
WO2009075886A1 (en) 2009-06-18
EP2610341B1 (en) 2014-09-17
AU2008335723C1 (en) 2013-05-30
AU2008335723A1 (en) 2009-06-18
JP2016104027A (en) 2016-06-09
SG10201408162PA (en) 2015-01-29
WO2009075886A8 (en) 2010-11-11
EP2584038A1 (en) 2013-04-24
CN103911378A (en) 2014-07-09
EP2610341A1 (en) 2013-07-03
CA2904904A1 (en) 2009-06-18
EP2610340A1 (en) 2013-07-03
US20090226470A1 (en) 2009-09-10
AU2008335723B2 (en) 2012-12-13
US8785611B2 (en) 2014-07-22
EP2231859B1 (en) 2013-01-23
EP2527439A2 (en) 2012-11-28
EP2527439A3 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
SG10201408164XA (en) Compositions and methods related to mrna translational enhancer elements
MX2010004674A (en) Alpha-amylase variants with altered properties.
IN2012DN00403A (en)
MX2009009948A (en) Pyridazinone derivatives useful as glucan synthase inhibitors.
MX2011006645A (en) Polypeptides with xylanase activity.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MY158106A (en) Inhibitors of e1 activating enzymes
PT1991680E (en) System for the expression of orthogonal translation components in eubacterial host cells
MX2010006933A (en) Compositions and methods for reducing or preventing water loss from the skin.
MY147970A (en) 2'-fluoro-2'deoxytetrahydrouridines as cytidine deaminase inhibitors
HK1149950A1 (en) Novel compositions and related methods, coatings, and articles
WO2008104979A3 (en) Nuclear targeting sequences
MX2020005458A (en) Alpha-amylase variants and polynucleotides encoding same.
MX2010003328A (en) Cell-permeabilising peptides and polypeptides for microbial cells.
WO2011084553A3 (en) Compositions and uses of cis-1,1,1,4,4,4-hexafluoro-2-butene
MY159575A (en) Dihydroorotate dehydrogenase inhibitors
MY155242A (en) Antireflective coating compositions
MX301786B (en) Variant buttiauxella sp. phytases having altered properties.
MX2010000593A (en) Increasing plant vigor.
WO2008109142A3 (en) Pirna and uses related thereto
BRPI1015043A2 (en) diazahomoadamantane derivatives and methods of use thereof
WO2011140527A3 (en) Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase
ATE497976T1 (en) T CELL RECEPTORS BINDING SPECIFICALLY TO VYGFVRACL-HLA-A24
MX345474B (en) Styrenic (meth)acrylic oligomers.
UA100127C2 (en) Peptide cdh3 and drug containing it